Ezetimibe
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is a cholesterol absorption inhibitor originally developed to lower LDL cholesterol in hypercholesterolemia, used alone or combined with a statin. The TxGNN model predicts it may also be effective for Hyperlipoproteinemia, a prediction supported by 50 clinical trials (19 disease-matched via PubMed search) and 19 publications, including multiple completed Phase 3 RCTs. Because hyperlipoproteinemia sits within the drug's already-established pharmacology, this reads less as a novel mechanistic leap and more as a formal extension of existing use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia (LDL-C/total cholesterol lowering, alone or with a statin) |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, a structured DrugBank mechanism-of-action record is not available for this drug in the Evidence Pack (Data Gap DG002). Based on the repurposing rationale attached to this candidate: ezetimibe selectively inhibits the NPC1L1 transporter at the intestinal brush border, blocking absorption of dietary and biliary cholesterol (and plant sterols). This reduces chylomicron-cholesterol delivery to the liver, which compensatorily upregulates hepatic LDL receptors and lowers LDL-C and other apoB-containing lipoproteins.
Hyperlipoproteinemia is the broader clinical category that encompasses elevated LDL-C and mixed lipid disorders — essentially the pathophysiology ezetimibe's core mechanism already targets. This is not a mechanistic extrapolation into a new disease area; it is the drug's on-label pharmacological action being formally mapped onto a related diagnostic category.
The clinical trial record reinforces this: ezetimibe has been studied as monotherapy, in fixed-dose combinations with statins/fenofibrate/bempedoic acid, and as an active comparator arm in numerous Phase 3 trials for mixed hyperlipidemia and hypercholesterolemia, giving this prediction unusually strong real-world clinical support for a TxGNN-derived candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00093899 | Phase 3 | Completed | 611 | Ezetimibe/simvastatin + fenofibrate coadministration evaluated for cholesterol-lowering effect in mixed hyperlipidemia (high cholesterol + high triglycerides) |
| NCT01763827 | Phase 3 | Completed | 615 | Evolocumab vs. placebo and ezetimibe (active comparator) on LDL-C change in low-Framingham-risk hypercholesterolemic adults |
| NCT06005597 | Phase 3 | Completed | 407 | Obicetrapib 10mg/ezetimibe 10mg fixed-dose combination on top of maximally tolerated therapy in HeFH/ASCVD patients |
| NCT01043380 | Phase 4 | Completed | 245 | IVUS-measured coronary plaque regression comparing cholesterol absorption inhibitor (ezetimibe) vs. synthesis inhibitor |
| NCT04433533 | Phase 4 | Unknown | 200 | Rosuvastatin/ezetimibe combination vs. rosuvastatin monotherapy in Korean patients with LV diastolic dysfunction and hyperlipidemia |
| NCT00092560 | Phase 3 | Completed | 587 | Fenofibrate and ezetimibe coadministration for cholesterol-lowering safety/efficacy in mixed hyperlipidemia |
| NCT00092573 | Phase 3 | Completed | 576 | Companion Phase 3 study of fenofibrate/ezetimibe coadministration in mixed hyperlipidemia |
| NCT00349284 | Phase 3 | Completed | 181 | Fenofibrate vs. ezetimibe vs. combination in Type IIb dyslipidemia with metabolic syndrome features |
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10mg add-on to atorvastatin or simvastatin in homozygous familial hypercholesterolemia |
| NCT00705211 | N/A | Completed | 1794 | 52-week Japanese post-marketing surveillance of Zetia (ezetimibe) mono/combination therapy safety and efficacy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM Phase 3 RCT: obicetrapib/ezetimibe fixed-dose combination significantly reduces LDL-C |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide RCT in heterozygous FH, a population historically treated with ezetimibe-based regimens |
| 37762244 | 2023 | Review | Int J Mol Sci | Pathophysiology, diagnosis and treatment of postprandial hyperlipidemia and its link to atherosclerosis |
| 40682836 | 2025 | Review | Mol Med Rep | Review of current drugs targeting hyperlipidemia and ASCVD prevention |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | Comprehensive review of PCSK9 inhibitors for patients not achieving LDL-C goals on statins/ezetimibe |
| 33766264 | 2021 | Review | J Am Coll Cardiol | New and emerging LDL-C/apoB-lowering therapies, positioning ezetimibe within the treatment landscape |
| 30702994 | 2019 | Review | Circulation Research | Overview of cholesterol-lowering agents including ezetimibe and PCSK9 inhibitors |
| 25939291 | 2015 | Review | Cardiology Clinics | Familial hypercholesterolemia management, citing statins, ezetimibe, and LDL apheresis as core therapies |
| 19654419 | 2009 | Review | Drug and Therapeutics Bulletin | Update on ezetimibe's LDL/total cholesterol-lowering effect alone or combined with statins |
| 18376001 | 2008 | Editorial | New England Journal of Medicine | Editorial commentary on cholesterol lowering and ezetimibe |
Finland Market Information
Ezetimibe is currently not marketed in Finland according to this Evidence Pack — 0 marketing authorizations are on file (taiwan_regulatory.total_licenses = 0, market_status = 未上市). No Fimea license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. (The Evidence Pack's key warnings, contraindications, and DDI lookup are all unpopulated — DG001, "TFDA/Fimea package insert warnings and contraindications," is flagged as a Blocking data gap that must be resolved before a full safety assessment can proceed.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication is strongly supported — evidence level L1, with multiple completed Phase 3 RCTs directly evaluating ezetimibe (alone or in fixed-dose combination) in hyperlipoproteinemia/mixed hyperlipidemia populations, and the mechanism is ezetimibe's already-established pharmacology rather than a novel hypothesis. However, the drug is not currently marketed in Finland and local safety/label data is entirely absent, so guardrails are required before any local development or communication.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently Blocking (DG001)
- Structured DrugBank MOA record to formally close DG002
- Finland-specific regulatory pathway assessment given current "not marketed" status (0 authorizations)
- Drug-drug interaction data (current DDI query returned
not_found)Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.